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INTRODUCTION 
The lung’s exceptionally large surface area, and minimal 
distance between the blood and external environment leave it 
vulnerable to infection. Most importantly is-that pulmonary 
infections can often lead to severe complications such as 
sepsis or septic shock. We are interested in pulmonary 
Plasmacytoid Dendritic Cells (pDC) which in other organs of 
the body have been shown to be critical in fighting severe 
infection through the initiation of inflammation and the 
modulation of T cell responses [1, 2]. We hypothesize that 
pDC, are prepositioned in the lung and are capable of rapidly 
responding to pathogenic insults. 
 
METHODS 
Lungs were exsanguinated and excised from the mouse and 
prepared as a whole lung homogenate. The cells were then Fc 
blocked and then stained with the antibody cocktail. Following 
the staining, the cells were analysed using flow cytometry.  
 
RESULTS 
Using flow-cytometry, we have identified pDC using the cell 
surface markers PDCA-1+ and Siglec-H+ within 
exsanguinated unstimulated whole lung homogenates.  
Analysing the anatomical locations of lung pDC revealed at 
baseline, pDC are almost exclusively located in the pulmonary 
vasculature with a small population in the lung parenchyma 
and none within the alveolus. pDC make up 0.5 % of total 
CD45+ pulmonary leukocytes.  Stimulating the lung with 
pathogen associated molecular patterns that directly or 
indirectly activate pDC demonstrated that early on during 
inflammation the absolute number of pDC does not change, 
suggesting they are not recruitable. Following stimulation, the 
population of PDCA-1+ cells increased; however, using our 
more rigorous definition of pDC by employing multiple cell 
surface markers we discovered that the true pDC population 
(PDCA-1+/Siglec-H+) did not change in number. Under 
unstimulated conditions, PDCA-1+ pDC were visualized 
within the vasculature. These cells crawled along the 
endothelium and were not part of the blood cellular blood 
flow. Following 24 hours of stimulation with a TLR 9 agonist, 
an increase in the total number of the PDCA-1+ was observed. 
The PDCA-1+ cells displayed a mix of a crawling and 
stationary phenotype. 
Figure 1. Up-regulation of PDCA-1 on Siglec H- populations 
24 hours following stimulation with a TLR 9 agonist. 
 
DISCUSSION AND CONCLUSIONS 
We have examined in detail our current definitions of pDC, 
the phenotypic markers used in the identification of them, their 
anatomical location within the lung, and finally the effects of 
two TLR agonists on pDC. We created an assay to identify the 
anatomical locations of pulmonary leukocytes, and developed 
methods to identify the roles that these cells play in pulmonary 
host defence. PDCA-1 is not an effective marker for pDC 
during inflammatory conditions and a rigorous definition of 
pDC is needed to identify them during inflammatory 
conditions. We made the novel observation that pDC, upon 
stimulation will react differently depending on the stimuli, 
meaning they display plasticity in their roles within the 
hierarchy of host defence. These findings provide the basis for 
further insight into the nature of pulmonary pDC and their 
roles in pulmonary inflammation. We will explore these 
exciting new avenues by asking questions regarding the roles 
and interactions which pDC have in the initiation of severe 
pneumonia, and its functions during. This work will allow us 
to continue to investigate the unknown roles and functions that 
pDC play during pulmonary inflammation, which will reveal 
exciting new pathways to treat severe pneumonia, or 
pulmonary inflammation. 
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